{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '1851 Harbor Bay Parkway',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 25,
 'askSize': 1200,
 'averageDailyVolume10Day': 1935312,
 'averageVolume': 2864201,
 'averageVolume10days': 1935312,
 'beta': 1.52549,
 'beta3Year': None,
 'bid': 24.34,
 'bidSize': 1800,
 'bookValue': 5.715,
 'category': None,
 'circulatingSupply': None,
 'city': 'Alameda',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 24.737,
 'dayLow': 24.09,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': -0.358,
 'enterpriseToEbitda': 19.087,
 'enterpriseToRevenue': 6.775,
 'enterpriseValue': 6634254848,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650 837 8300',
 'fiftyDayAverage': 23.62457,
 'fiftyTwoWeekHigh': 27.8,
 'fiftyTwoWeekLow': 13.67,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 276290374,
 'forwardEps': 0.88,
 'forwardPE': 27.943182,
 'fromCurrency': None,
 'fullTimeEmployees': 617,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.030199999,
 'heldPercentInstitutions': 0.78894997,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/exelixis.com',
 'longBusinessSummary': 'Exelixis, Inc., an oncology-focused biotechnology '
                        'company, focuses on the discovery, development, and '
                        'commercialization of new medicines to treat cancers '
                        "in the United States. The company's products include "
                        'CABOMETYX tablets for the treatment of patients with '
                        'advanced renal cell carcinoma who received prior '
                        'anti-angiogenic therapy; and COMETRIQ capsules for '
                        'the treatment of patients with progressive and '
                        'metastatic medullary thyroid cancer. Its CABOMETYX '
                        'and COMETRIQ are derived from cabozantinib, an '
                        'inhibitor of multiple tyrosine kinases, including '
                        'MET, AXL, RET, and VEGF receptors. The company also '
                        'offers COTELLIC, an inhibitor of MEK as a combination '
                        'regimen to treat advanced melanoma; and MINNEBRO, an '
                        'oral non-steroidal selective blocker of the '
                        'mineralocorticoid receptor for the treatment of '
                        'hypertension in Japan. In addition, Exelixis, Inc. is '
                        'developing XL092, an oral tyrosine kinase inhibitor '
                        'that targets VEGF receptors, MET, and other kinases '
                        'implicated in growth and spread of cancer. It has '
                        'collaboration and license agreement with Ipsen Pharma '
                        'SAS, Takeda Pharmaceutical Company Ltd., Roche, '
                        'Aurigene Discovery Technologies Limited, Iconic '
                        'Therapeutics, Inc., Invenra, Inc., StemSynergy '
                        'Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, '
                        'Bristol-Myers Squibb Company, Merck, Daiichi Sankyo '
                        'Company, Limited, and clinical collaboration with '
                        'Ipsen. The company was formerly known as Exelixis '
                        'Pharmaceuticals, Inc. and changed its name to '
                        'Exelixis, Inc. in February 2000. Exelixis, Inc. was '
                        'founded in 1994 and is headquartered in Alameda, '
                        'California.',
 'longName': 'Exelixis, Inc.',
 'market': 'us_market',
 'marketCap': 7540745216,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_28338',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 293848992,
 'nextFiscalYearEnd': 1640908800,
 'open': 24.73,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 1.16,
 'phone': '650 837 7000',
 'previousClose': 24.98,
 'priceHint': 2,
 'priceToBook': 4.302712,
 'priceToSalesTrailing12Months': 7.7009006,
 'profitMargins': 0.30009001,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 24.737,
 'regularMarketDayLow': 24.09,
 'regularMarketOpen': 24.73,
 'regularMarketPreviousClose': 24.98,
 'regularMarketPrice': 24.73,
 'regularMarketVolume': 1763739,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 306659008,
 'sharesPercentSharesOut': 0.0438,
 'sharesShort': 13426653,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 14884532,
 'shortName': 'Exelixis, Inc.',
 'shortPercentOfFloat': 0.0496,
 'shortRatio': 5.07,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'EXEL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.93,
 'trailingPE': 26.44086,
 'twoHundredDayAverage': 21.251726,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '3d2b06c7-e4e4-3c4b-a972-6c6bfa8d57a3',
 'volume': 1763739,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.exelixis.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94502'}